Phase II Study of E7389 Administered as an IV Bolus Infusion Day 1 and Day 8 Every 3 Weeks in Pre-Treated Patients With Advanced and/or Metastatic Soft Tissue Sarcoma.

Trial Profile

Phase II Study of E7389 Administered as an IV Bolus Infusion Day 1 and Day 8 Every 3 Weeks in Pre-Treated Patients With Advanced and/or Metastatic Soft Tissue Sarcoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Mar 2017

At a glance

  • Drugs Eribulin (Primary)
  • Indications Haemangiosarcoma; Leiomyosarcoma; Liposarcoma; Rhabdomyosarcoma; Sarcoma; Soft tissue sarcoma; Synovial sarcoma
  • Focus Therapeutic Use
  • Sponsors Eisai Inc
  • Most Recent Events

    • 24 May 2016 According to Eisai media release, data of this trial will be presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO), in June 2016.
    • 23 Apr 2014 Status changed from discontinued to completed as reported by ClinicalTrials.gov
    • 30 Jun 2012 Planned number of patients changed from 128 to 160 as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top